Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
10 March 2017
E-001659-17
Question for written answer
to the Commission
Rule 130
Mairead McGuinness (PPE)

 Subject:  Bacteriophages
 Answer(s) 

The use of antibiotics in livestock production is under scrutiny, with concern spreading over the rise of microbial resistance. In the veterinary sector, resistance to antibiotics has been observed.

To reduce the need for antibiotics in the human food chain, the use of bacteriophages offers significant unrealised potential. In particular, it is known that bacteriophages can substantially reduce the level of Campylobacter infection in chicken, which has a high incidence rate across EU. In the case of Enterococcus, salmonella and E. coli, for example, antibiotics are currently the only method of treatment, whereas bacteriophages can provide a non-antibiotic alternative.

Is the Commission considering including bacteriophages, as an effective replacement for antibiotics, in the legal framework governing medicinal products for veterinary use?

Regarding the EU Phagoburn project, what are the results of the trial, and what policies will be adopted as a consequence?

Last updated: 28 March 2017Legal notice